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Norovirus is a major cause of acute gastroenteritis in humans. A norovirus outbreak occurred in Ohio in
January 2010. Stool and saliva samples were obtained from six infected individuals. The full-length genomes
of two representative strains (HS206 and HS210) were characterized. They belonged to GII.12 in the capsid but
GII.g in the RNA polymerase region. Interestingly, an immunocompetent 2-year-old male shed virus for up to
30 days, as detected by real-time reverse transcription (RT)-PCR. Histo-blood group antigen (HBGA) typing
of saliva showed that the norovirus strains infected various types of secretor-positive individuals (types A, B,
and O). The viruslike particles of strain HS206 did not bind substantially to A/B/O antigens by synthetic HBGA
binding, hemagglutination, or saliva binding assays. These results suggest that infection by this strain may not
be A/B/O antigen dependent or that in vitro binding patterns do not always accurately reflect in vivo HBGA
usage. This is different from the HBGA binding pattern of the previously reported GII.12/Aichi76 strain.
Structural analysis of the predicted capsid of these GII.12 strains revealed two amino acid mismatches located
near the HBGA binding sites. Four gnotobiotic pigs were inoculated orally with HS206 (6  1010 genomic
equivalents [GE]/pig). Virus shedding began at postinoculation days (PID) 1 to 3 and continued up to PID 16
(1  105 to 2  107 GE/ml). Gastroenteritis cases caused by GII.12 noroviruses have been recently reported
worldwide. We observed that this emerging GII.12 norovirus infected humans regardless of A/B/O blood type.
The infection of pigs by strain HS206 suggests that interspecies transmission of this strain is possible under
experimental conditions.
Norovirus (NoV) is a major cause of nonbacterial acute
gastroenteritis in both children and adults (17, 52, 54). Out-
breaks are common in confined environments such as families,
hospitals, and schools, and secondary attack rates are as high
as 30% in these settings (22). Small numbers of infectious
particles can cause infection (67). Virus shedding from patients
recovered from illness (2, 46, 57, 63) or from asymptomatic
individuals (1, 2, 21, 51) has been well documented, rendering
control more difficult.
Norovirus, a member of the family Caliciviridae, has a single-
stranded, positive-sense RNA genome of 7.3 to 7.7 kb, which
encodes 3 open reading frames (ORFs) (23). ORF1 encodes a
polyprotein that is cleaved by the virus-encoded protease to
produce several nonstructural proteins, including the RNA-
dependent RNA polymerase (RdRp), while ORF2 encodes a
major capsid protein (VP1), and ORF3 encodes a minor struc-
tural protein (VP2) (3, 26). The capsid protein consists of a
conserved shell (S) domain and a variable protruding (P) do-
main (55). Noroviruses are genetically diverse and are cur-
rently classified into five genogroups (GI to GV), with each
genogroup being further divided into multiple genotypes (75).
Among them, GI, GII, and GIV strains infect humans, with
GII being the most prevalent and genetically diverse, including
some GII NoV strains of swine origin (71, 75). Genotyping
based on the complete capsid region remains the gold standard
(32, 70, 75), and more than 30 genotypes have been designated,
with the GII.4 genotype being dominant in humans. However,
RNA recombination complicates genetic classification, since
recombinant strains cluster within two distinct genotypes when
different genomic regions (mainly before and after the ORF1-
ORF2 junction region) are subjected to phylogenetic analysis (7,
8, 53). Consequently, genotyping based on the ORF1 (RdRp)
region has been proposed (5, 8, 21), and numerous recombi-
nant strains designated by RdRp genotype/capsid genotype
have been reported, such as GI.2/GI.6 (33), GII.b/GII.3 (4, 13,
16), GII.b/GII.16 (15), GII.3/GII.13 (14), GII.4/GII.3 (15),
GII.4/GII.12 (18), GII7/GII13 (47), and GIII.2/GIII.1 (8).
Norovirus recognizes histo-blood group antigens (HBGAs)
as receptors or coreceptors (29, 39). In humans, HBGAs are
complex carbohydrates present on red blood cells, and, in most
of the population who have an active FUT2 gene, also on the
surface of mucosal epithelial cells, as well as in body fluids such
as saliva (secretor positive [Se]) (68). Associations between
HBGA phenotypes, secretor status, and susceptibility to cer-
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tain NoV strains have been reported. In studies with human
volunteers, individuals with blood type B had a decreased risk
of infection, and nonsecretors were resistant to Norwalk virus
(GI.1) infection (29, 39), whereas individuals were equally sus-
ceptible to Snow Mountain virus (SMV) (GII.2) regardless of
their HBGA or secretor status (38). Nonsecretors were resis-
tant to GII.3 and GII.4 NoVs, and individuals with blood type
A were more susceptible to GII.4 strains in outbreak cases
(65). There have been few reports on HBGA types and secre-
tor statuses for uncommon NoV genotype infections (50).
Gnotobiotic (Gn) pigs are susceptible to strains of the dom-
inant human NoV genotype, GII.4 (strain HS66) (12, 61, 62),
and are an important animal model for human NoV infection.
The detection of human NoV RNA in swine (48) and the high
prevalence of antibodies against human GI and GII NoVs in
porcine sera (19) raise questions as to the possible interspecies
transmission of NoVs between humans and pigs. It is of inter-
est, therefore, to expand previous studies to determine if other
emerging new strains infect Gn pigs.
In this study, we delineate the clinical course of recent NoV
outbreak cases in Ohio and characterize the full-length ge-
nomes of two representative strains. Viruslike particles (VLPs)
of one strain were expressed in the baculovirus expression
system and were used to examine its HBGA binding pattern.
Three-dimensional (3D) structural analysis was performed to
investigate the differences between current and previously re-
ported GII.12 strains. Finally, Gn pigs were inoculated with
one strain (HS206) to investigate whether it infects pigs and,
thus, its potential for interspecies transmission between hu-
mans and pigs.
MATERIALS AND METHODS
Outbreak profile and sample collection. From 9 January to 5 February 2010,
14 people from eight families in the departmental staff or their family members
reported symptoms of acute gastroenteritis (vomiting and/or diarrhea) to the
calicivirus research team at the Food Animal Health Research Program of the
Ohio Agricultural Research Development Center, The Ohio State University,
Wooster, OH. Fresh stool samples (total, 37) were provided voluntarily from six
persons (patients A to F) from two families (families 1 and 2) (Table 1). None
of them suffered from any underlying disease. An additional sample (strain
HS239) was provided by patient A in July 2010 as a potential negative control
when patient A had been free of symptoms for 4 months. Saliva samples were
also provided by each person for HBGA typing (56). All the samples were
immediately deidentified by the investigators so that only coded-log-number
samples were used.
RNA extraction and viral detection/titration from stool samples. Sample RNA
was extracted from 10% (wt/vol) stool suspensions in sterile minimal essential
medium (MEM; Invitrogen, Carlsbad, CA) by using a MagMAX viral RNA
isolation kit (Applied Biosystems, Foster City, CA) according to the manufac-
turer’s instructions. Subsequently, RNA was screened for common diarrheal
viruses, including GI and GII NoVs; human rotavirus groups A, B, and C;
sapovirus; astrovirus; and adenovirus, by reverse transcription (RT)-PCR or
PCR assays as described previously (31, 72, 73). All the stool samples were
titrated in duplicate for GII NoV by real-time RT-PCR (31), with a standard
curve generated from serial dilutions of plasmid DNA carrying the GII.4/HS66-
specific COG2F/2R amplicon.
Sequence analysis of NoV strains. The full-length genomes of two represen-
tative strains (HS206 from family 1 and HS210 from family 2) were character-
ized. The primers were designed based on the conserved regions among GII NoV
genomes reported to date (Table 2). The cDNA was generated by using a
SuperScript III first-strand cDNA synthesis kit (Invitrogen) and amplified with
Takara Ex Taq polymerase (TaKaRa Mirus Bio, Madison, WI) according to the
manufacturer’s instructions. Three independent RT-PCR assays were conducted
to determine the consensus genome sequences. First, two overlapping cDNAs
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primers Noro-F1-R1 and Noro-F2-R, respectively. The first-round PCRs were
carried out with primer sets Noro-F1-F/Noro-F1-R1 and Noro-F2-F1/Noro-
F2-R, respectively. Seminested secondary PCRs were performed with primer sets
Noro-F1-F/Noro-F1-R2 and Noro-F2-F2/Noro-F2-R, respectively. The 5 end of
the NoV genome was determined by the 5 rapid amplification of cDNA ends
(5-RACE) system according to the manufacturer’s instructions (Invitrogen).
The 3 end of the norovirus genome was characterized according to a 3-end
cDNA amplification protocol described previously (58).
For patient A, the complete capsid was amplified for samples from different
time points in his infection course (HS200 at 3 days, HS207 at 7 days, and HS234
at 30 days after the onset of disease) to investigate if mutations occurred during
the month-long infection. First-round PCR was performed by using primer pairs
p290 and QO, followed by second-round PCR with primer pair Mon431 and QI
(27, 49, 51). To obtain the consensus sequence of capsid sequences of HS200,
HS207, and HS234, five independent clones of each strain were selected for
sequence analysis. Capsid region C was amplified for samples from the remaining
patients (patient D [HS209], patient E [HS224], and patient F [HS219]) and from
HS239 from patient A, collected in July 2010, by using primer set COG2F and
G2-SKR for genotyping (31, 32, 70).
The PCR products were purified by use of the QIAquick gel extraction kit
(Qiagen, Inc.) before direct sequencing or cloning into the PCR XL vector by
using a TOPO XL PCR cloning kit for sequencing (Invitrogen). BigDye Termi-
nator cycle sequencing and an ABI prism 3100 Genetic Analyzer (Applied
Biosystems) were used to obtain DNA sequence data. Sequence editing was
carried out by using the Lasergene software package (version 8; DNASTAR Inc.,
Madison, WI). The Basic Local Alignment Search Tool (BLAST) (http://www
.ncbi.nlm.nih.gov/BLAST) was used to find homologous hits. Multiple-sequence
alignment was performed by using CLUSTAL W software (version 2) (36). A
phylogenetic tree with 1,000 bootstrap replicates of the sequence alignment data
sets was generated by using the neighbor-joining method with MEGA (version 4)
(64). Recombination analysis was performed by using Simplot software (version
1.3) (http://sray.med.som.jhmi.edu/SCRoftware/simplot/). NoV reference strains
used for analysis are summarized in the table in the supplemental material.
Genotype (capsid) reference strains whose complete ORF1 to ORF3 sequences
were available in the GenBank database were used. Representative GII.4 NoVs
were selected to represent each branch in a GII.4 phylogenetic tree (45). Ref-
erence strains for RdRp genotypes are included only when the assigned genotype
numbers differ from the capsid genotypes according to the nomenclature pro-
posed by the National Institute for Public Health and the Environment, Neth-
erlands (35).
Expression and purification of HS206 VLPs. The recombinant baculovirus
carrying the ORF2 and ORF3 genes of HS206 was generated by using the
BaculoDirect baculovirus expression system (Invitrogen) according to the man-
ufacturer’s instructions. Briefly, a Gateway entry clone containing the ORF2 and
ORF3 genes of HS206 (pENTR/SD/D-TOPO-HS206) was generated and used
with BaculoDirect linear DNA to perform an LR recombination reaction to
generate recombinant baculovirus DNA carrying the HS206 genes. Insect Sf9
cells were transfected by the recombination reaction products, and the cells
containing recombinant baculovirus DNA were positively selected by use of
ganciclovir. The expression of HS206 capsid proteins in Sf9 cells and culture
supernatants was examined by immunoblotting using guinea pig antiserum
against Hu/NoV/GII.4/HS191. The recombinant baculoviruses (rBac-HS206)
were propagated to prepare virus stocks with high titers for routine VLP expres-
sions.
The production and purification of HS206 VLPs were performed as described
previously (24). Briefly, Sf9 cells were infected with rBac-HS206 at a multiplicity
of infection of 5 to 10. The cell culture supernatants were harvested at postin-
oculation day (PID) 7. The VLPs were purified by ultracentrifugation through a
40% (wt/vol) sucrose cushion, followed by CsCl isopycnic gradient (0.39 g/ml)
ultracentrifugation. The protein concentration of the VLPs was measured with
Bradford reagent (Sigma-Aldrich, St. Louis, MO). The VLPs were negatively
stained with 3% phosphotungstic acid (pH 7.0) and examined by transmission
electron microscopy (EM) as described previously (24). The HS206 VLPs that
were confirmed by EM to contain the correct morphologies of particles were
used for hemagglutination (HA), saliva-VLP binding, and synthetic HBGA-VLP
binding assays.
Screening of rabbit antisera against NoV VLPs. GII.12/HS206 VLPs were
characterized by an enzyme-linked immunosorbent assay (ELISA), as described
previously (41). Plates were coated at 1 g/ml VLP in phosphate-buffered saline
(PBS) for 4 h at room temperature and blocked overnight at 4°C in 5% Carna-
tion dry milk in PBS–0.05% Tween 20 before the addition of rabbit anti-NoV
polyclonal sera and incubation for 45 min, followed by anti-rabbit IgG-horse-
radish peroxidase (HRP) (Sigma-Aldrich) for 30 min and color development
with 1-Step Ultra TMB ELISA HRP substrate solution (Thermo Fischer Scien-
tific Inc., Rockford, IL). All incubations were completed at room temperature.
Each step was followed by washing with PBS–0.05% Tween 20, and all antibodies
were diluted in 5% Carnation dry milk in PBS–0.05% Tween 20. All samples
were assayed in triplicate. Antibodies were considered positive for reactivity if
the mean optical density for VLP-coated wells was greater than three times the
mean optical density for PBS-coated wells.
Carbohydrate binding assays. Viruslike particle binding to HBGA-pheno-
typed boiled salivary samples and synthetic biotinylated HBGAs (GlycoTech,
Gaithersburg, MD) was determined as previously reported (40, 42), except as
noted. Saliva samples were diluted 1:200 for plate coating, and bound VLPs were
detected by rabbit anti-GI and anti-GII NoV pooled polyclonal serum followed
by anti-rabbit IgG-HRP and 1-Step Ultra TMB ELISA HRP substrate solution.
All assays were performed at room temperature. Binding was considered positive
for ligand reactivity if the mean optical density for carbohydrate-coated wells was
greater than three times the mean optical density for PBS-coated wells.
HA assay. An HA assay was performed as described previously (30). Briefly, 50
l of 0.5% packed human red blood cells (RBCs) (Immucor, Norcross, GA) was
combined with an equal volume of serially diluted VLPs (starting concentration
of 4 g/ml) at three different pHs (0.01 M PBS for pH 6.8 and pH 7.4 and citric
acid-Na2HPO4-buffered saline [5 mM citric acid, 0.01 M Na2HPO4, and 0.85%
NaCl] for pH 5.5) at three different temperatures (4°C, room temperature, and
37°C). Inactivated human influenza virus (strain Hum/OH/K1130/06) and the Sf9
cell protein were used as positive and negative controls, respectively. The HA
titer was the reciprocal of the highest sample dilution that completely blocked
the sedimentation of the RBCs.
Structure analysis. Three-dimensional structural models of the capsid P-do-
main dimers were constructed by MOE-Align and MOE-Homology in the Mo-
lecular Operating Environment (MOE; Chemical Computing Group, Inc., Mon-
treal, Quebec, Canada), as described previously (44, 45), for strains HS206,
HS210, and GII.12/Aichi76 (59). Briefly, the P-domain monomer models were
first constructed by using the crystal structure of the capsid P domain of strain
GII.4/VA387 at a resolution of 2.00 Å (Protein Data Bank [PDB] accession
number 2OBS [9]) as the template. P-domain dimer models were constructed
based on the P-domain monomer models by superimposing chains A and B using
the crystal structure of the GI.1/Norwalk virus capsid dimer as a template (PDB
accession number 1IHM [55]).
Inoculation of Gn pigs. Near-term pigs were derived by surgery and main-
tained in sterile isolator units as previously described (43). Six-day-old Gn pigs
were allocated into the HS206-inoculated (pigs 1 to 4) or mock-inoculated
control (pigs 5 and 6) group. A single aliquoted pool of the original human fecal
sample obtained from patient B (strain HS206) was used for the oral inoculation
of the Gn pigs. Each Gn pig received one oral dose of the NoV inoculum,
consisting of the original HS206 strain diluted 10% (wt/vol) in MEM, which was
processed by vortexing, centrifugation at 1,800  g for 30 min, and filtration
TABLE 2. Primers designed in this study
Primer Nucleotide sequence (5–3) Polarity Positionsa
Noro-F1-F GTGAATGAAGATGGCGTCTAACGAC Sense 1–25
Noro-F1-R1 CTCCAGAATTTGGTTTTAGTAC Antisense 3645–3666
Noro-F1-R2 GTCATTTCCTCTCTTGTAGATGTATGG Antisense 3458–3484
Noro-F2-F1 GGTCTACTGGAGAGCTGATGCC Sense 3300–3321
Noro-F2-F2 GCGCACTGTTGGAGGGCAGATG Sense 3367–3388
Noro-F2-R GCGCCAGTCCAGGAGTCCAAAAC Antisense 7391–7413
a Location based on HS206.
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through 0.2-m-pore-size filters. The viral titer of the inoculum was 2.4  1010
genomic equivalents (GE)/ml, and 6.0  1010 GE was used per pig. The mock
inoculum was the same volume of MEM. Two HS206-inoculated pigs (pigs 1and
3) and 1 mock-inoculated control pig (pig 5) were euthanized at the acute phase
(PID 4), and the rest were euthanized at the convalescent phase (PID 22). Rectal
swabs were collected daily for the detection of diarrhea and virus shedding. Fecal
consistency was scored as follows, with scores of 2 or higher being considered
diarrheic: 0, solid; 1, pasty; 2, semiliquid; 3, liquid (12). HBGA typing of exper-
imental pigs was done on formalin-fixed, paraffin-embedded intestinal and buccal
tissues by immunofluorescent staining as described previously (11). The pigs
were maintained in accordance with the guidelines of the Institutional Animal
Care and Use Committee of The Ohio State University.
Nucleotide sequence accession numbers. The sequences determined in this
study were submitted to the GenBank database under the following accession num-
bers: GU325839 (Hu/NoV/GII.4/HS194/09/US), HQ664990 (Hu/NoV/GII.12/
HS206/10/US), HQ401025 (Hu/NoV/GII.12/HS207/10/US), HQ449728 (Hu/NoV/
GII.12/HS210/10/US), HQ880574 (Hu/N0V/GII.6/HS239/l0/US), JN022612 (Hu/
NoV/GII.6/HS245/10/US), and JN022613 (Hu/NoV/GII.2/HS255/11/US).
RESULTS
GII.12 NoV (capsid) was identified from the gastroenteritis
outbreak. The screening of the first 6 stool samples collected
from each of the six individuals of the two families for diar-
rheal viruses by RT-PCR or PCR resulted in the exclusive
detection of GII NoV in all of the samples. Sequence analysis
of the samples provided by all the patients revealed that strains
detected from the same family were identical in capsid region
C (282 nucleotides [nt]) and belonged to GII.12 (32, 70). Clin-
ical symptoms, HBGA typing of saliva, and NoV GII viral
shedding of each individual are summarized in Table 1. A
9-month-old girl (patient D, saliva type B) shed high titers of
NoV (2.5  1012 GE/ml) but without any clinical symptoms.
The titer remained high (1.8  1011 GE/ml) for at least 6
days. The asymptomatic excretion of NoV was recorded for all
6 patients. The complete course of virus shedding was exam-
ined for patient A (Fig. 1), who shed virus up to 30 days after
the onset of diarrhea but for 20 days without symptoms. Inter-
estingly, all infected individuals were secretor positive and had
diverse HBGA types (types A, B, and O), while the two B
phenotype individuals did not show clinical symptoms.
Because patient A shed NoV for 1 month, we analyzed the
complete capsid region of the viral genomes from three fecal
samples from this patient, HS200, HS207, and HS234, at 3, 7,
and 30 days after onset of illness, respectively, to examine if
mutations occurred in the viral genome in this immunocom-
petent boy. We found no mutations during the course of this
1-month infection (Fig. 2).The sample provided from this pa-
tient as a control when he was free of symptoms in July 2010
(HS239) turned out to be NoV positive and was of GII.6 by
sequence analysis of capsid region C.
Full-length genome analyses of two representative strains
revealed that they were potentially recombinant strains (GII.g
[RdRp]/GII.12 [capsid]). Strain HS206 from family 1 and
strain HS210 from family 2 were subjected to full-length ge-
nome sequence analysis. Both strains shared high genomic
identity (98.7% nucleotide identity). A BLAST search showed
that they shared the highest genomic identity (99.0 to 99.2%
nucleotide identity) with strain NSW199U, detected in a sporadic
case in Australia in 2008 (16). Strain HS206 was compared for
each ORF region with capsid (ORF2) genotype reference
strains that have been completely sequenced (total, 36) (Ta-
ble 3). Complete genome sequences were not available in
GenBank for certain genotypes (GII.5, GII.7, GII.9, GII.13,
GII.14, GII.15, GII.17, GII.18, GII.19, GII.20, and GII.21).
For our analysis, previously reported recombinant strains
(GII.c/GII.2 Snow Mountain virus [27], GII.4/GII.3 CBNU1
[74], GII.4/GII.10 Mc37 [25], GII.4/GII.12 Gifu96, and GII.4/
GII.12 Saitama U1 [18]) were excluded from the ORF1 anal-
ysis to avoid confusion. Strikingly higher identities were found
for all ORFs (88.3 to 99.2% nucleotide identity and 94.4 to
100.0% amino acid identity) between HS206 and NSW199U than
with the other genotypes of NoV strains. As expected, the lowest
genomic identity (53.4 to 62.6% nucleotide identity and 50.4 to
67.5% amino acid identity) was with the porcine GII.11 NoV.
Based on the capsid sequences, HS206 and HS210 clearly
clustered with GII.12 together with NSW199U and other
GII.12 reference strains (Fig. 2) (75). In contrast, our strains
and NSW199U clustered in the distinct GII.g lineage in the
partial RdRp region (780 nt), according to the nomenclature
proposed by the National Institute for Public Health and the
Environment, Netherlands (Fig. 3) (35). Because no ORF1 of
GII.12 strains other than strain NSW199U has been identified
to date, the GII.g ORF1 could be the corresponding GII.12
ORF1, or a recombination event may have occurred between
two distinct genotypes of NoVs, GII.g (RdRp) and GII.12
(capsid). Simplot analysis was carried out by placing the 3-end
ORF1 (RdRp) and ORF2 of HS206 as a query sequence and
the corresponding sequences of GII.12 (capsid) reference
strain Gifu96 and GII.g (RdRp) reference strain Goulburn
Valley as background sequences (Fig. 4). The HS206 strain
shared a high level of identity with strain Goulburn Valley in
the RdRp, but the identity decreased in the capsid region,
where it shared a high level of identity with the Gifu96 strain.
The breakpoint of recombination was predicted where these
two parental strains shared the same identity (i.e., where the
curves cross) at the ORF1-ORF2 overlap region (around nu-
cleotide position 1150 in Fig. 4).
HS206 VLPs did not bind substantially to any HBGA types
tested. To characterize the new strain more completely, we
constructed VLPs of a representative outbreak strain (HS206)
to investigate their HBGA binding patterns and compare them
with those of other well-characterized NoV strains. First, to
determine the antigenic properties of HS206 relative to those
of previously characterized strains, VLPs were screened for
reactivity to a panel of rabbit anti-NoV sera by ELISA. As
expected, GI.1/Norwalk VLPs reacted with the anti-GI NoV
FIG. 1. Fecal virus shedding of GII NoV and clinical symptoms of
patient A (2-year-old male). Samples analyzed for complete capsid
sequences are marked by circles.
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sera but with none of the anti-GII sera, while GII.4/1997,
GII.1/Hawaii, and GII.2/Snow Mountain virus (SMV) reacted
with antisera directed against genogroup II VLPs. HS206
VLPs reacted with all the anti-NoV sera similarly to the GII.1/
Hawaii VLPs (Fig. 5).
By using pooled NoV antisera as detecting antibodies, the
profiles of binding of HS206 VLPs to synthetic HBGAs was
tested (Fig. 6A). While GI.1/Norwalk VLPs bound to H type 1,
H type 3, and the Lewis B and A trimer and GII.4/1997 bound
to H type 3 and the Lewis Y, A, and B trimer, as reported
previously (40, 42), HS206 VLPs did not bind to any of the
tested HBGAs under the assay conditions used.
To investigate the properties of the binding of HS206 VLPs
to biological HBGAs, we performed a VLP-saliva binding as-
say using saliva from GII.12-infected patients in this outbreak
and an HA assay using commercial human pooled RBCs. In
the VLP-saliva binding assay, GI.1/Norwalk VLPs bound to
saliva types O and A at high levels but bound to type B only at
room temperature and at a lower level, as reported previously
(40, 42). GII.4/1997 VLPs bound to saliva types O, A, and B at
low levels. GII.2/SMV VLPs bound to type B saliva at a low
level (28), and GII.1/Hawaii VLPs bound weakly to type B
saliva, just above the cutoff value. HS206 VLPs did not bind to
any saliva HBGA type when 1 g/ml of VLPs was used but
bound to type B saliva weakly when 5 g/ml of VLPs was used
(Fig. 6B).
In the HA assays, the negative-control Sf9 cell proteins did not
hemagglutinate any RBCs, whereas the positive influenza virus
control gave HA titers of 128 to 256 under all the pHs (pH 5.5,
6.8, and 7.4) and temperature (4°C, room temperature, and 37°C)
FIG. 2. Neighbor-joining phylogenetic analysis of GII NoVs based on the complete capsid region (535 to 557 amino acids). The newly
sequenced strains in this study are in italic type. Bootstrap values are provided as percentages of 1,000 replicates for values of 70%.
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conditions tested. HS206 VLPs did not hemagglutinate any RBC
types at any pHs and incubation temperatures tested.
Mismatches between our strains and Aichi76 within the P2
domain are located near the HBGA binding sites. Since pre-
viously reported GII.12 (capsid) strain Aichi76 bound to saliva
from type B individuals (6 out of 6), we further analyzed if the
sequences of these strains are different at critical HBGA bind-
ing sites. When the GII.12 NoV strains in this study (HS206
and HS210) and Aichi76 were aligned at the capsid region, 9
and 11 amino acid mismatches were noted for HS206 and
HS210, respectively (data not shown). Among the 8 amino acid
mismatches that were common for both strains, 2 amino acid
mismatches were in the most variable P2 domain, E373Q and
N392S. By 3D structural analysis, the two amino acids were
located in the vicinity of the HBGA binding interfaces (site I,
positions 343 to 347; site II, position 374; site III, positions 440
to 443 [in the GII.4/VA387 strain]) (66) in the P-domain dimer
structural models generated by homology modeling (Fig. 7).
Although the shape of the binding pocket was not predicted to
have changed, the negatively charged amino acid residue (E) at
position 373 became a neutral amino acid (Q).
HS206 infected Gn pigs. To investigate whether this emerg-
ing new strain infects pigs and, thus, its potential for interspe-
cies transmission between humans and pigs, Gn pigs were
inoculated with HS206. HS206-inoculated Gn pigs shed virus
from PID 1 to 3, which coincided with mild diarrhea (fecal
consistency score of 2) in pig 1 (Fig. 8). The virus titer peaked
(1.8  106 to 1.7  107 GE/ml) from PID 2 to 5. The longest
duration of virus shedding, up to PID 16, was observed for pig
4, which was euthanized at PID 16. Neither of the two mock-
inoculated pigs shed virus or had diarrhea. All the HBGA phe-
notypes of the experimental pigs were determined to be A.
DISCUSSION
For decades, GII.4 was the predominant genotype among
NoV gastroenteritis outbreaks. In this study, we identified
new GII.g/GII.12 strains from a gastroenteritis outbreak in
Wooster, OH, in January 2010. Similar strains caused sporadic
FIG. 3. Neighbor-joining phylogenetic analysis of GII NoVs based on
the 3 end of the RNA-dependent RNA polymerase region (780 nt). The
newly sequenced strains in this study are in italic type. Bootstrap values
are provided as percentages of 1,000 replicates for values of 70%.
TABLE 3. Sequence identity between HS206 and other completely sequenced reference strains based on available
genotypes (capsid) in genogroup II
Genogroup and genotype (capsid)
(no. of strains analyzed)
% sequence identitya
ORF1 ORF2 ORF3
Nucleotide Amino acid Nucleotide Amino acid Nucleotide Amino acid
GII.1 (1) 82.7 94.2 74.8 86.4 88.1 94.4
GII.2 (2) 77.1b 90.9b 68.7–69.0 74.9–76.2 67.2–68.4 69.8–71.2
GII.3 (4) 73.7–81.7c 87.0–93.8c 62.3–62.8 69.2–70.5 66.5–67.7 74.1–76.9
GII.4 (16) 81.5–82.9 94.2–94.4 59.8–60.1 60.9–62.8 59.1–61.4 53.0–54.7
GII.6 (5) 62.7–63.4 71.3–71.5 62.9–64.3 69.2–71.0 62.0–65.5 66.0–69.0
GII.8 (1) 64.3 71.3 60.9 65.6 65.2 65.3
GII.10 (2) 71.6d 93.9d 67.8–68.2 78.2–78.4 70.1 77.5–78.9
GII.11 (1) 62.6 67.5 59.8 64.5 53.4 50.4
GII.12 (3) 99.2e 99.6e 90.5–99.1 97.6–99.6 88.3–99.1 94.4–100.0
GII.16 (1) 72.6 87.2 70.0 80.6 80.8 84.8
a The highest identities for each ORF are highlighted in boldface type. Recombinant strains were excluded for the ORF1 analysis.
b Snow Mountain (GII.c/GII.2) was excluded from the ORF1 analysis.
c CBNU1 (GII.4/GII.3) was excluded from the ORF1 analysis.
d Mc37 (GII.4/GII.10) was excluded from the ORF1 analysis.
e Gifu96 and SaitamaU1 (GII.4/GII.12) were excluded from the ORF1 analysis.
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gastroenteritis cases in Australia in 2008 (16) and food-borne
outbreaks in Hungary, France, and the Netherlands from 2009
to 2010 (20). GII.12 (capsid) strains were also reported to have
caused 32 outbreaks from October 2009 to March 2010 in the
United States (69). These findings suggest the emergence of
GII.12 (capsid) NoV strains worldwide in 2008 to 2010. This
was probably due to their escape from existing herd immunity
to previously prevalent genotypes, such as GII.4 (22). Further
monitoring of the epidemiological trends for NoV infections is
warranted.
Among the 6 individuals involved in this study, patient A
was asymptomatically infected with GII.6 NoV (strain HS239)
4 months later and was infected together with his mother
(patient B, strain HS256) with NoV GII.2 (strain HS255), with
vomiting and diarrhea, 1 year after the GII.12 infection, re-
spectively. Patient C had been symptomatically infected with
NoV GII.4 (strain HS194), with diarrhea and vomiting, 1 year
prior and was infected together with his sister (patient D, stain
HS246), his father (patient E, strain HS244), and his mother
(patient F, strain HS247) with NoV GII.6 (HS245), with vom-
iting and diarrhea, 11 months after the GII.12 infection, re-
spectively (our unpublished data). Except for strain HS194, for
which the genome has been sequenced, the other strain geno-
types were characterized based on region C sequence analysis.
These results suggest that intergenotype protection from NoV
infection is lacking.
The GII.12 strains from the two families were very similar,
falling into the same lineage in phylogenetic trees based on
both the capsid and RdRp regions, but are apparently different
strains showing 1.3% nucleotide diversity in the complete ge-
nome, suggesting that the sources of infection of the 2 families
differed.
There are increasing reports of prolonged NoV shedding de-
tected by RT-PCR even in immunocompetent patients. Rockx et
al. (57) reported previously that 26 of 99 NoV-infected children
shed NoV for up to 22 days after the onset of illness. Murata
et al. (46) found previously that infants less than 6 months old
shed NoV for up to 47 days. Kirkwood and Streitberg (34)
reported the shedding of a GII.4 strain in a 21-month-old child
for 100 days, and Siebenga et al. (60) described the shedding of
a GII.3 strain in a 4-month-old infant for 34 days. These find-
ings may reflect the increased sensitivity of detection by RT-
PCR and real-time RT-PCR assays. However, little sequence
information on the NoVs detected during prolonged virus
shedding has been reported. In our study, the complete capsids
of three samples (collected at 3, 7, and 30 days after the onset
of illness) from patient A, who is immunocompetent and shed
virus for 1 month, were sequenced. Surprisingly, no mutations
were noted among the three samples in the complete capsid
region. In studies of immunocompromised patients, a NoV
GII.3 strain accumulated 32 amino acid mutations in the com-
plete capsid region during 1 year of infection (49), and a GII.4
NoV strain accumulated 11 amino acid mutations during 119
days of infection (60). In the latter study, those authors re-
ported that a GII.3 NoV mutated more in an immunocompe-
tent patient than in immunocompromised patients, suggesting
FIG. 4. Simplot analysis of strain HS206. The partial genome of HS206 covering the ORF1/ORF2 overlap region was analyzed for recombi-
nation events. The window size was 200 nt, and the step size was 20 nt. At each position of the window, the query sequence (HS206) was compared
to each of the background genotype representatives (GII.12 Gifu96 and GII.d Goulburn Valley). The nucleotide positions of ORF1 and ORF2
are indicated beneath the diagram.
FIG. 5. Screening of rabbit antisera for antibody reactivity against
NoV VLPs. Plates were coated with VLPs before the addition of rabbit
anti-norovirus polyclonal sera. Anti-rabbit IgG-HRP was added, and
color was developed with 1-Step Ultra TMB ELISA HRP substrate
solution. OD, optical density.
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an immune-driven selection of mutants. Those authors also
noted lower mutation rates in GII.3 than in GII.4 NoV strains
in their patients. Recently, Bull et al. (6) confirmed by in vitro
experiments that GII.4 strains had a higher substitution rate
than did GII.3 and GII.7 strains. These results suggest that
genotype/strain differences play an important role in NoV evo-
lution. To date, our study is the first to depict the prolonged
shedding of a NoV GII.12 strain in an immunocompetent child
up to 30 days after the onset of gastroenteritis. Whether the
viruses in asymptomatically infected individuals detected by
real-time RT-PCR are infectious or not remains uncertain (22,
63), and until an effective cell culture system for NoV is estab-
lished to examine infectivity, hygienic precautions should be
implemented even after the symptoms have subsided.
Another interesting finding of the current study was that
individuals of various HBGA types (types A, B, and O) were
infected with GII.12 strains, although the two type B individ-
uals remained asymptomatic. Whether the two type B individ-
uals were infected previously with a NoV that provided partial
protection is unknown. When we analyzed the binding pattern
of VLPs of one representative strain from this outbreak
(HS206), we found little if any binding to any synthetic or
biological (those expressed on RBCs and those secreted in
saliva) HBGAs that were evaluated. All these assays were
performed in vitro at room temperature and might not repre-
sent the binding properties of NoV in vivo. Nevertheless, these
in vitro results were consistent with the clinical profile that
HS206 infected individuals regardless of A, B, or O phenotype.
This clinical pattern is similar to that observed previously for
GII.2/SMV infection in a volunteer study, which was not type
A/B/O dependent (38). A seroprevalence study using donated
blood also revealed that the presence of IgG titers against
GII.4 strain was type A/B/O independent but correlated with
the secretor phenotype (37). In another report, symptomatic
GII.4 infections were also strongly associated with the Se
FIG. 6. Binding assay of VLPs of HS206. (A) Binding between
VLPs and synthetic histo-blood group carbohydrates. A neutravidin-
coated plate was incubated with biotin-labeled synthetic HBGA car-
bohydrates. The binding of VLPs to HBGAs was detected by rabbit
anti-GI and anti-GII NoV pooled polyclonal sera. (B) Binding be-
tween VLPs and saliva from HS206- or HS210-infected individuals.
Plates were coated with boiled saliva at a 1:200 dilution. The binding
of VLPs to saliva was detected by rabbit anti-GI and anti-GII NoV
pooled polyclonal sera.
FIG. 7. Location of amino acid mismatches in the P2 domain
among the GII.12 NoV strains from a study described previously by
Shirato et. al (59) (Aichi76 strain) and the strains in this outbreak
(HS206 and HS210). Shown are P-domain dimer structures of the
three strains. HBGA binding interfaces (sites I to III) and two different
amino acid changes (E373Q and N392S) from the Aichi76 strain are
shown in orange and aqua, respectively. A to C are top views and D to
F are magnified views of HBGA binding interfaces of Aichi76, HS206,
and HS210, respectively.
FIG. 8. Fecal virus shedding in four Gn pigs inoculated with NoV
HS206 determined by real-time RT-PCR. Arrows indicate diarrhea in
a pig. PID, postinoculation day.
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phenotype (10). Although all the individuals in the current
outbreak were Se, it is hard to conclude that GII.12 infection
is Se dependent without Se-negative (Se) individuals ex-
posed to these GII.12 strains. Higher concentrations of HS206
VLPs did not give positive results in the HA assay (40 g/ml)
or in VLP-synthetic HBGA binding assays (5 g/ml), whereas
they bound weakly to type B saliva at a concentration of 5
g/ml, suggesting that they have low-affinity binding to the B
antigen. Of note, this pattern is very similar to that of
GII.1/Hawaii, which lacks synthetic HBGA binding (28) yet
weakly binds to type B saliva (Fig. 6B). In addition, GII.12/
HS206 and GII.1/Hawaii VLPs react similarly to rabbit anti-
NoV sera (Fig. 5). These VLPs also reacted with mouse
anti-NoV sera in a similar pattern: among mouse anti-GI.1/
Norwalk virus, anti-GII.1/Hawaii, anti-GII.2/SMV, and anti
GII.4/1997 antisera, they reacted with anti-GII.1/Hawaii and
anti-GII.2/SMV sera but with not anti-GI.1/Norwalk virus and
anti-GII.4/1997 sera (data not shown). These similarities may
be explained by the high sequence identity in the ORF2 region
(Table 3) (74.8% nucleotide identity and 86.4% amino acid
identity) between these two strains among GII NoVs.
The GII.12/Aichi76 strain bound to saliva from type B indi-
viduals (6 out of 6) (59). The authors of that study used the
same concentration of VLPs (1 g/ml) as we did but more-
diluted saliva (1:1,600) in the VLP-saliva binding assay. How-
ever, the current GII.12/HS206 VLPs did not bind to saliva
from type B individual at 1 g/ml, but the VLPs bound at a
higher concentration (5 g/ml). These results suggest that
HS206 was a weak binder to the B antigen. These differences
between the two GII NoV strains (Aichi76 and HS206) could
be due to their different capsid sequences, especially at the P2
domain that is exposed on the surface of virus particles. To
determine if the sequences of these GII.12 strains are different
at critical HBGA binding sites of the P2 domain, we analyzed
the P-domain dimer structural models generated by homology
modeling. Two amino acid mismatches between our strains
and strain Aichi76, E373Q and N392S, were predicted to be
located in the vicinity of the HBGA binding interfaces. These
changes did not induce any detectable changes in the structural
shape. However, the change at position 373 alters a negatively
charged residue to a neutral amino acid. In many cases, the
electrostatic interaction affects the binding affinity. Therefore,
we speculate that E373Q would impact the affinity of binding
between virus particles and ligands and might have contributed
to the difference of binding patterns between the two GII.12
human NoV strains HS206 and Aichi76.
The assigned nomenclature for RdRp genotypes is unclear
and has resulted in the naming of almost identical sequence
strains as different genotypes, such as the identification of
NSW199U as being of GII.e/GII.12 in one publication (16) but
GII.g/GII.12 in our analysis. In our study, we followed the
nomenclature developed by the National Institute for Public
Health and the Environment, Netherlands, as it includes the
widest range of reference strains in the database (35). In this
classification system for the RdRp region (780 nt), within-
genotype identities (amino acids) ranged from 89.9% (GII.8)
to 99.6% (GII.18), whereas intergenotype identities ranged
from 61.3% (between GII.a and GII.3) to 91.0% (between
GII.4 and GII.e), which indicates the difficulty of assigning a
clear cutoff percent identity to denote a genotype in this re-
gion.
The HS206 strain infected all four inoculated Gn pigs, as
documented by real-time RT-PCR. Three of the four pigs
began fecal virus shedding at PID 2 or 3, and in all four pigs,
virus titers first increased and then decreased after the onset of
virus shedding. This fecal virus shedding pattern was similar to
that of human volunteers infected with GI.1/Norwalk virus,
who showed peak fecal virus titers at 2 to 4 days after oral
inoculation, which decreased progressively thereafter (2). Al-
though the viral titers in the feces were lower than that in the
original inocula, we were unable to accurately calculate the
total amount of virus shed due to difficulties in collecting all
the feces separately from isolator units. The Gn pigs infected
with human rotavirus presented similar fecal shedding pat-
terns. Rotavirus-inoculated pigs displayed obvious diarrhea,
but the rotavirus titers in the feces were 100- to 1,000-fold
lower than the titers of the inocula, as determined by a fluo-
rescent-focus assay (A. Vlasova and L. J. Saif, unpublished
data). Moreover, in Gn pigs inoculated with a heat-inactivated
NoV GII.4 strain, no viral RNA was detected in feces, sug-
gesting that infectious virus was detected by our real-time
RT-PCR (K. Jung and L. J. Saif, unpublished data). Collec-
tively, these data support our assertion that the viral RNA
detected was not from pass-through inocula, in which case
initially high and progressively decreasing titers would occur.
Our data suggest that the interspecies transmission of a human
GII.12 strain to pigs is possible under experimental conditions,
as was previously observed for a human GII.4 NoV strain (12).
In summary, we detected and characterized GII.g (RdRp)/
GII.12 (capsid) NoVs from a gastroenteritis outbreak in Wooster,
OH. Prolonged virus shedding (1 month) was documented in one
immunocompetent child in this outbreak, reemphasizing the im-
portance of hygienic precautions. The results of HBGA typing of
saliva of infected individuals confirmed that A, B, and O HBGA
Se types were all susceptible to this strain, and the finding
that HS206 VLPs did not bind substantially to any HBGA in
vitro supports the speculation that infection by this strain is not
A/B/O antigen dependent. The new GII.12 strain infected
young Gn piglets, confirming the interspecies transmission of
human NoVs to pigs under experimental conditions.
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